Knowing stock market today at a glance

Glaukos Plunges 11.07% Despite Sales Surge

Mover TrackerThursday, May 1, 2025 7:26 am ET

1min read

Glaukos's stock price plummeted by 11.07% in pre-market trading on May 1, 2025, marking a significant decline for the company.

Glaukos reported a quarterly loss of $0.22 per share for the first quarter of 2025, which was better than the estimated loss of $0.33 per share. The company's operating loss for the first quarter of 2025 was $20.7 million, a notable improvement from the $39.1 million operating loss in the same period last year.

Despite the loss, glaukos saw a 25% increase in net sales for the quarter, reaffirming its full-year guidance. The company's revenue for the first quarter reached $106.7 million, surpassing market projections of $102.8 million. This growth was attributed to the successful execution of key strategic plans and the advancement of its pipeline of novel, dropless platform technologies.

Glaukos's chairman and chief executive officer, Thomas Burns, highlighted the company's strong start to the year and sustained growth acceleration. He emphasized the company's commitment to advancing the standard of care and improving outcomes for patients suffering from chronic eye diseases.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.